Table 2.
Clinical characteristics of individual cancer patients.
|
Solid tumours | |||||||||||||||
|
Patient number |
Sex |
Age |
PS |
Diabetes |
BMI |
HTA |
Other comorbidities |
Concurrent ongoing therapies |
Cancer localisation |
Metastatic disease Y/N |
Active anticancer treatment during 4 weeks before COVID infection |
Time between COVID-19 infection and blood sample in days |
COVID-19 serology |
At least one specific T-cell response (S, M or N) |
CEF specific T-cell responses |
| 03–01 | M | 72 | 1 | NO | 27.7 | YES | NO | NO | Hepatocarcinoma | YES | Sorafenib | 64,0 | POS | NO | YES |
| 03–02 | F | 53 | 0 | NO | 26.5 | NO | NO | NO | Breast | YES | Trastuzumab Pertuzumab Hormonotherapy | 72,0 | POS | YES | YES |
| 03–03 | M | 55 | 3 | NO | 23.8 | NO | Arrhythmia | Amlodipine Cordarone Perindopril |
Pulmonary | NO | Durvalumab | 85,0 | POS | YES | YES |
| 03–05 | F | 75 | 1 | NO | 26.5 | YES | NO | NO | Breast | YES | Hormonotherapy | 70,0 | POS | YES | YES |
| 03–06 | M | 62 | 3 | NO | 24.3 | YES | Arrhythmia | Sotalol Apixaban |
HNC | YES | NO | 54,0 | NEG | NO | YES |
| 03–07 | M | 69 | 2 | NO | 19.8 | YES | NO | NO | HNC | YES | Methotrexate | 48,0 | POS | YES | YES |
| 03–10 | F | 69 | 0 | NO | 24.8 | NO | Dyslipidemia | Pravastatine | Colorectal | YES | FOLFOX | 63,0 | POS | YES | YES |
| 03–14 | F | 75 | 1 | NO | 21.5 | NO | NO | NO | Breast | YES | Capecitabine Lapatinib | 85,0 | POS | NO | YES |
| 03–15 | M | 73 | 1 | NO | 18 | NO | NO | NO | Pulmonary | YES | Cisplatin Pemetrexed Prembrolizumab | 58,0 | POS | NO | NO |
| 03–16 | F | 48 | 1 | NO | 24.4 | NO | NO | NO | Breast | NO | Trastuzumab | 61,0 | POS | NO | NO |
| 03–17 | F | 74 | 0 | NO | 18.6 | NO | NO | NO | Glioblastoma | YES | NO | 59,0 | POS | NO | YES |
| 03–18 | F | 62 | 0 | NO | 22.3 | NO | NO | NO | Breast | YES | Tucatinib Capecitabine Trastuzumab | 85,0 | POS | NO | YES |
| 03–19 | M | 67 | 1 | NO | 20.5 | YES | NO | NO | Stomach | YES | FOLFIRI | 67,0 | POS | NO | YES |
| 03–20 | F | 64 | 1 | NO | 21 | NO | NO | NO | Ovarian | YES | Liposomal doxorubicin | 60,0 | POS | NO | NO |
| 03–21 | F | 57 | 1 | NO | 40 | YES | NO | NO | Ovarian | YES | Carboplatin Paclitaxel | 83,0 | POS | YES | YES |
| 03–22 | F | 71 | 0 | NO | 22 | NO | NO | NO | Breast | NO | NO | 91,0 | POS | YES | YES |
| 03–23 | M | 72 | 2 | NO | 21 | NO | NO | NO | Colorectal | YES | FOLFOX Bevacizumab | 71,0 | POS | YES | YES |
| 03–24 | M | 70 | 0 | NO | 21 | NO | NO | NO | Vesical | NO | NO | 81,0 | POS | YES | YES |
| 03–25 | M | 74 | 1 | NO | 19.8 | NO | NO | NO | HNC | NO | DCF | 69,0 | POS | YES | NO |
| 03–26 | M | 84 | 1 | NO | 22.6 | NO | NO | NO | Renal | YES | Nivolumab | 65,0 | POS | NO | NO |
| 03–27 | F | 80 | 0 | YES | 26 | NO | NO | NO | Hepatocarcinoma | YES | Sorafenib | 56,0 | POS | NO | YES |
| 03–28 | F | 62 | 0 | NO | 19.3 | NO | NO | NO | Breast | NO | Docetaxel | 75,0 | POS | NO | NO |
| 03–29 | F | 70 | 0 | NO | 31 | YES | NO | NO | Breast | YES | Palbociclib Hormonotherapy | 85,0 | POS | NO | NO |
| 03–31 | M | 75 | 2 | NO | 20 | NO | Ischemia Cardiopathy - Chronic Renal Failure |
Sotalol Perindopril Metformin Lercanidipine | Pulmonary | YES | NO | 70,0 | NEG | YES | YES |
| 03–34 | F | 64 | 1 | NO | 25 | NO | NO | NO | Renal | YES | Nivolumab | 101,0 | NEG | YES | YES |
| 03–40 | M | 74 | 1 | YES | 24.7 | YES | NO | NO | Prostate | YES | Cabazitaxel | 89 | POS | YES | NO |
| 03–42 | F | 51 | 2 | NO | 20 | YES | NO | NO | Sarcoma | NO | NO | 109 | POS | YES | YES |
| 03–44 |
F |
58 |
1 |
NO |
19 |
YES |
NO |
Hydrochlorothiazide |
Pancreas |
YES |
Gemcitabine |
41 |
POS |
NO |
YES |
|
Haematological malignancies | |||||||||||||||
|
Patient number |
Sex |
Age |
PS |
Diabetes |
BMI |
HTA |
Other comorbidities |
Concurrent ongoing therapies |
Cancer localisation |
Disease stage |
Active anticancer treatment during 4 weeks before COVID infection |
Time between COVID-19 infection and blood sample in months |
COVID-19 serology |
At least one T cell response (S, M or N) |
CEF specific T-cell responses |
| 03–12 | M | 73 | 1 | NO | 1.72 | NO | NO | NO | DLBCL | Early | R–CHOP | 49 | NEG | YES | YES |
| 03–13 | M | 23 | 1 | NO | 2.5 | NO | NO | Valaciclovir Tacrolimus Prednisone |
ALL | Early | NO (allograft in October 2019) | 48 | NEG | NO | YES |
| 03–32 | M | 80 | 1 | NO | 2 | YES | NO | Sotalol | CLL | Early | R-Venetoclax | 80 | POS | YES | NO |
| 03–35 | F | 48 | 2 | YES | 1.4 | NO | Pulmonary transplantation | Tacrolimus | AML | Early | NO (Allograft in 2006) | 48 | NEG | NO | NO |
| 03–36 | M | 54 | 1 | NO | 2 | NO | NO | Tacrolimus | AML | Early | NO (Allograft in august 2019) | 54 | POS | NO | NO |
| 03–37 | M | 54 | 2 | NO | 1.9 | NO | NO | Prednisone Polyvalent Intravenous Immunoglobulin |
AML | Early | NO (Allograft in 2007) | 54 | POS | YES | YES |
| 03–38 | M | 72 | 1 | NO | 1.8 | YES | Hypothyroidism | Levothyroxine | Multiple myeloma | Late | Isatuximab Pomalidomide Dexamethasone |
72 | POS | YES | YES |
| 03–39 | F | 73 | 2 | NO | 1.7 | NO | Stroke | Valaciclovir | AML | Late | Venetoclax | 73 | POS | NO | YES |
| 03–41 | M | 67 | 1 | NO | 2.1 | NO | Arrhythmia | Prednisone | Myelodysplastic syndrome | Late | NO | 67 | NEG | NO | YES |
| 03–43 | F | 52 | 1 | NO | 2.2 | NO | Hypothyroidism | Levothyroxine | CML | Early | Nilotinib | 52 | POS | NO | NO |
| 03–46 | M | 66 | 1 | NO | 2.1 | NO | NO | Valaciclovir Irbesartan | Bone marrow failure | Early | Cyclosporine | 66 | NEG | NO | YES |
Abbreviation: ALL, Acute Lymphocytic Leukaemia; AML, Acute Myelogenous Leukaemia; CLL, Chronic Lymphocytic Leukaemia; CML, Chronic Myelogenous Leukaemia; DCF, Docetaxel Cisplatin Fluorouracil; DLBC, Diffuse Large B Cell Lymphoma; F, Female; HNC, Head and Neck Cancer; M, Male; PS, Performance Status.